| Literature DB >> 3542210 |
J H Edmonson, G W McCormack, J E Krook, H J Long, J A Jefferies, R L Richardson.
Abstract
Six patients with histologically proven stage III-IV ovarian carcinoma received carboplatin (CBDCA) (150 mg/m2) plus cyclophosphamide (1000 mg/m2) monthly for 1 year unless disease progressed earlier. Six other patients received CBDCA (225 mg/m2) with the same cyclophosphamide dose monthly. Continued treatment with the higher CBDCA dose was not tolerable because of myelosuppression, but no other dose-limiting toxic effect was observed. Complete tumor regression was proven at secondary laparotomy in six of the 12 patients, and five of these remain disease-free from 26+ to 28+ months after beginning chemotherapy.Entities:
Mesh：
Substances：
Year: 1987 PMID： 3542210
Source DB: PubMed Journal: Cancer Treat Rep ISSN： 0361-5960